The Role of Endogenous Hormones in the Etiology and Prevention of Breast Cancer: The Epidemiological Evidence

  • Paola Muti
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 166)


Breast cancer is the most common cause of cancer death in women worldwide. Rates vary about fivefold around the world, but they are increasing in regions that until recently had low rates of disease. Despite the numerous uncertainties surrounding the etiology of breast cancer, intensive epidemiological, clinical, and genetic studies have identified a number of biological and social traits as risk factors associated with breast cancer. Principal among them is the evidence of BRCA1 and BRCA2 susceptibility genes, familial history of breast cancer, age, higher socioeconomic status, ionizing radiation, tallness in adult life, alcohol consumption, and a variety of hormone and metabolic factors. Among the hormonal influences, a relevant etiological function has been ascribed to unopposed exposure to elevated levels of estrogens and androgens. In addition, new epidemiologic evidence has indicated that among the metabolic factors, glucose metabolism, hyperinsulinemic insulin resistance, and insulin-like growth factor bioavailability may also play a role in breast cancer. These endocrine and metabolic factors may represent future targets for breast cancer prevention.


Breast Cancer Breast Cancer Risk Premenopausal Woman Breast Cancer Case Natl Cancer Inst 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    International Agency for Research on Cancer (1987) Overall evaluations of carcinogenicity: an updating of IARC monograph volumes 1 to 42. IARC monograph on the evaluation of carcinogenic risk to humans. Suppl 7. Lyon, pp 272–310Google Scholar
  2. 2.
    Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49:8–31PubMedGoogle Scholar
  3. 3.
    Mettlin C (1999) Global breast cancer mortality statistics, 1999. CA Cancer J Clin 49:138–144PubMedCrossRefGoogle Scholar
  4. 4.
    Bernstein L, Ross RK (1993) Endogenous hormones and breast cancer risk. Epidemiol Rev 15:48–65PubMedGoogle Scholar
  5. 5.
    Russo J, Hu YF, Yang X, Russo IH (2000) Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr 27:17–37PubMedGoogle Scholar
  6. 6.
    Secreto G, Recchione C, Fariselli G, Di Pietro S (1984) High testosterone and low progesterone circulating levels in premenopausal patients with hyperplasia and cancer of the breast. Cancer Res 44:841–844PubMedGoogle Scholar
  7. 7.
    Secreto G, Toniolo P, Pisani P, Recchione C, Cavalleri A, Fariselli G, Totis A, Di Pietro S, Berrino F (1989) Androgens and breast cancer in premenopausal women. Cancer Res 49:471–476PubMedGoogle Scholar
  8. 8.
    Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104–207Google Scholar
  9. 9.
    Lacassagne A (1932) Apparition de cancers de la mamelle chez la souris male, soumise à des injections de folliculine. CR Acad Sci 195:630–632Google Scholar
  10. 10.
    Parlin DM, Whelan J, Ferlay L, Raymond L, Young J (eds) (1997) Cancer incidence in five continents, vol. VII. International Agency for Research on Cancer Scientific Publications, LyonGoogle Scholar
  11. 11.
    Cavalieri E, Frenkel K, Liehr JG, Rogan, Roy D (2000) Estrogens as endogenous genotoxic agents-DNA adducts and mutation. J Natl Cancer Inst Monogr 27:75–94PubMedGoogle Scholar
  12. 12.
    Flölotto T, Djahansouzi S, Gläser M, Hanstein B, Niederacher D, Brumm C, Beckmann MW (2001) Hormones and hormones antagonists: mechanism of action in carcinogenesis of endometrial and breast cancer. Horm Metab Res 33:451–457Google Scholar
  13. 13.
    Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, et al (1996) Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 5:533–539PubMedGoogle Scholar
  14. 14.
    Dorgan JF, Stanczyk FZ, Longcope C, Stephenson HE Jr, Chang L, Miller R, et al (1997) Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3β,17β-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 6:177–181PubMedGoogle Scholar
  15. 15.
    Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, et al (1997) A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br J Cancer 76:401–405PubMedGoogle Scholar
  16. 16.
    Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, et al (1998) Plasma sex steroid hormone levels and risk of breast cancer in post menopausal women. J Natl Cancer Inst 90:1292–1299PubMedCrossRefGoogle Scholar
  17. 17.
    Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, et al (1995) A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87:190–197PubMedGoogle Scholar
  18. 18.
    Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JMG, Koenig KL, Shore RE, Kim MY, et al (1997) Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol 145:1030–1038PubMedGoogle Scholar
  19. 19.
    Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, et al (1996) Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 88:291–296PubMedGoogle Scholar
  20. 20.
    Barrett-Connor E, Friedlander NJ, Khaw K-T (1990) Dehydroepiandrosterone sulfate and breast cancer risk. Cancer Res 50:6571–6574PubMedGoogle Scholar
  21. 21.
    Garland CF, Friedlander NJ, Barrett-Connor E, Khaw K-T (1992) Sex hormones and postmenopausal breast cancer: a prospective study in an adult community. Am J Epidemiol 135:1220–1230PubMedGoogle Scholar
  22. 22.
    Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE (2000) A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 9:575–579PubMedGoogle Scholar
  23. 23.
    Cauley JA, Lucas FL, Kuller LH, Stone K, Browner W, Cummings SR, for the Study of Osteoporotic Fractures Research Group (1999) Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med 130:270–277PubMedGoogle Scholar
  24. 24.
    Gordon GB, Bush TL, Helzlsouer KJ, Miller SR, Comstock GW (1990) Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res 50:3859–3862PubMedGoogle Scholar
  25. 25.
    Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW (1994) A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 18:79–85PubMedGoogle Scholar
  26. 26.
    Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616Google Scholar
  27. 27.
    James VH, McNeill JM, Lai LC, Newton CJ, Ghilchik MW, Reed MJ (1987) Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 50:269–279PubMedCrossRefGoogle Scholar
  28. 28.
    Berrino F, Muti P (1988) Overview of the etiological hypotheses linking endogenous steroid hormones and breast cancer. In: Riboli E, Saracci R (eds) Diet, hormones and cancer: methodological issues for prospective studies. IARC Technical Report No. 4, LyonGoogle Scholar
  29. 29.
    Wysowski DK, Comstock GW, Helsing KJ, Lau HL (1987) Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 125:791–799PubMedGoogle Scholar
  30. 30.
    Rosenberg CR, Pasternack BS, Shore RE, Koenig KL, Toniolo PG (1994) Premenopausal estradiol levels and the risks of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol 140:518–525PubMedGoogle Scholar
  31. 31.
    Key TJA, Wang DY, Brown JB, Hermon C, Allen DS, Moore JW, Bulbrook RD, Fentiman IS, Pike MC (1996) A prospective study of urinary oestrogen excretion and breast cancer risk. Br J Cancer 73:1615–1619PubMedGoogle Scholar
  32. 32.
    Thomas HV, Key TJ, Moore JW, Dowsett M, Fentiman IS, Wang DY (1997) A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 75:1075–1079PubMedGoogle Scholar
  33. 33.
    Kelsey JL, Gammon MD, John EM (1993) Reproductive factors and breast cancer. Epidemiol Rev 15:36–47PubMedGoogle Scholar
  34. 34.
    Catt KJ, Dufau ML (1991) Gonadotropic hormones: byosinthesis secretion, receptors, and action. In: Yes SS, Jaffe RB (eds) Reproductive endocrinology. Sauders and Company, Philadelphia, pp 105–155Google Scholar
  35. 35.
    Milazzo G, Giorgino F, Damante F, et al (1992) Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52:3924–3930PubMedGoogle Scholar
  36. 36.
    Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, Rosen N (1990) Insulin like growth factor receptor expression and function in human breast cancer. Cancer Res 50:48–53PubMedGoogle Scholar
  37. 37.
    Osborne CK, Clemmons DR, Arteaga CI (1990) Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol 37:805–809PubMedGoogle Scholar
  38. 38.
    Cara JF (1994) Insulin-like growth factors, insulin-like growth factor binding proteins and ovarian androgen production. Horm Res 42:49–54PubMedCrossRefGoogle Scholar
  39. 39.
    Barbieri RL, Makris A, Ryan KJ (1984) Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca. Obstet Gynecol 64:73S–80SPubMedGoogle Scholar
  40. 40.
    Nestler JE, Jakubowicz DJ (1996) Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome [see comments]. N Engl J Med 335:617–623PubMedCrossRefGoogle Scholar
  41. 41.
    Lewitt MS (1994) Role of the insulin-like growth factors in the endocrine control of glucose homeostasis. Diabetes Res Clin Pract 23:3–15PubMedCrossRefGoogle Scholar
  42. 42.
    Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34PubMedCrossRefGoogle Scholar
  43. 43.
    Rinderknecht E, Humbel RE (1978) Primary structure of human insulin-like growth factor II. FEBS Lett 89:283–286PubMedCrossRefGoogle Scholar
  44. 44.
    Salter J, Best CH (1953) Insulin as a growth hormone. Br Med J (Aug 15):353–358Google Scholar
  45. 45.
    Zapf J (1997) The IGF-insulin relationship. J Pediatr Endocrinol Metabol 10:87–95Google Scholar
  46. 46.
    Clemmons DR, Underwood LE (1991) Nutritional regulation of IGF-I and IGF binding proteins. Annu Rev Nutr 11:393–412PubMedCrossRefGoogle Scholar
  47. 47.
    Werner H, LeRoith D (1996) The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 68:183–223PubMedGoogle Scholar
  48. 48.
    Stewart CE, Rotwein P (1996) Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 76:1005–1026PubMedGoogle Scholar
  49. 49.
    Dickson RB, Lippman ME (1995) Growth factors in breast cancer. Endocr Rev 16:559–589PubMedCrossRefGoogle Scholar
  50. 50.
    Baserga R (1995) The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55:249–252PubMedGoogle Scholar
  51. 51.
    Berns EM, Klijn JG, van SI, Portengen H, Foekens JA (1992) Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52:1036–1039PubMedGoogle Scholar
  52. 52.
    Thissen JP, Ketelslegers JM, Underwood LE (1994) Nutritional regulation of the insulin-like growth factors. Endocr Rev 15:80–101PubMedCrossRefGoogle Scholar
  53. 53.
    Baxter RC, Turtle JR (1978) Regulation of hepatic growth hormone receptors by insulin. Biochem Biophys Res Commun 84:350–357PubMedCrossRefGoogle Scholar
  54. 54.
    Plymate SR, Jones RE, Matej LA, Friedl KE (1988) Regulation of sex hormone binding globulin (SHBG) production in Hep G2 cells by insulin. Steroids 52:339–340PubMedCrossRefGoogle Scholar
  55. 55.
    Crave JC, Lejeune H, Brebant C, Baret C, Pugeat M (1995) Differential effects of insulin and insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (Hep G2) cells. J Clin Endocrinol Metab 80:1283–1289PubMedGoogle Scholar
  56. 56.
    Stein P, Bussmann LE, Tesone M (1995) In vivo regulation of the steroidogenic activity of rat luteal cells by insulin. J Steroid Biochem Mol Biol 52:329–335PubMedCrossRefGoogle Scholar
  57. 57.
    Hankinson SE, Willett WC, Colditz GA, et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393–1396PubMedCrossRefGoogle Scholar
  58. 58.
    Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A (2000) Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88:828–832PubMedCrossRefGoogle Scholar
  59. 59.
    Muti P, Quattrin T, Grant B, Krogh V, Micheli A, Ram M, Freudenheim JL, Schünemann HJ, Sieri, S, Trevisan M, Berrino F (2002) Fasting glucose, insulin and insulin-like growth factor (IGF)-I pattern in relation to breast cancer risk: a prospective Study. Cancer Epidemiol Biomarkers Prev 11:1361–1368PubMedGoogle Scholar
  60. 60.
    Krajcik RA, Borofsky ND, Massardo S, Orentreich N (2002) Insulin-like growth factor I (IGF), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 11:1566–1573PubMedGoogle Scholar
  61. 61.
    Jernström H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, Pollak M (2001) Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 10(4):377–384PubMedGoogle Scholar
  62. 62.
    Warburg O (1956) On the origin of cancer cells. Science 123:309–314PubMedGoogle Scholar
  63. 63.
    Franco Berrino, Cristina Bellati, Giorgio Secreto, Edgarda Camerini, Valeria Pala, Salvatore Panico, Giovanni Allegro, Rudolf Kaaks (2001) Reducing bioavailable sex hormones through a comprehensive change in diet: the Diet and Androgens (DIANA) randomized trial. Cancer Epidemiol Biomarkers Prev 10:25–33PubMedGoogle Scholar
  64. 64.
    Rose DP, Connolly JM, Chlebowski RT, Buzzard IM, Wynder EL (1993) The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients. Breast Cancer Res Treat 27:253–262PubMedCrossRefGoogle Scholar
  65. 65.
    Schaefer EJ, Lichtenstein AH, Lamon-Fava S, McNamara JR, Schaefer MM, Rasmussen H, Ordovas JM (1995) Body weight and low-density lipoprotein cholesterol changes after consumption of a low-fat ad libitum diet. J Am Med Assoc 274:1450–1455CrossRefGoogle Scholar
  66. 66.
    Shah M, McGovern P, French S, Baxter J (1994) Comparison of a low-fat, ad libitum complex-carbohydrate diet with a low-energy diet in moderately obese women. Am J Clin Nutr 59:980–984PubMedGoogle Scholar
  67. 67.
    Grenman S, Ronnemaa T, Irjala K, Kaihola HL, Gronroos M (1986) Sex steroid, gonadotropin, cortisol, and prolactin levels in healthy, massively obese women: correlation with abdominal fat cell size and effect of weight reduction. J Clin Endocrinol Metab 63:1257–1261PubMedCrossRefGoogle Scholar
  68. 68.
    Svendsen OL, Hassager C, Christiansen C (1995) The response to treatment of overweight in postmenopausal women is not related to fat distribution. Int J Obes Relat Metab Disord 19:496–502PubMedGoogle Scholar
  69. 69.
    Kiddy, DS, Hamilton-Fairley, D, Seppala, M, Koistinen, R, James, VH, Reed, MJ, and Franks, S (1989) Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol (Oxf) 31:757–763Google Scholar
  70. 70.
    Guzick DS, Wing R, Smith D, Berga SL, Winters SJ (1994) Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 61:598–604PubMedGoogle Scholar
  71. 71.
    Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M (1995) Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 80:2057–2062PubMedGoogle Scholar
  72. 72.
    O’Dea JP, Wieland RG, Hallberg MC, Llerena LA, Zorn EM, Genuth SM (1979) Effect of dietary weight loss on sex steroid binding sex steroids, and gonadotropins in obese postmenopausal women. J Lab Clin Med 93:1004–1008PubMedGoogle Scholar
  73. 73.
    Bates GW, Whitworth NS (1982) Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil Steril 38:406–409PubMedGoogle Scholar
  74. 74.
    Ingram DM, Bennett FC, Willcox D, de Klerk N (1987) Effect of low-fat diet on female sex hormone levels. J Natl Cancer Inst 79:1225–1229PubMedGoogle Scholar
  75. 75.
    Prentice R, Thompson D, Clifford C, Gorbach S, Goldin B, Byar D (1990) Dietary fat reduction and plasma estradiol concentration in healthy postmenopausal women. The Women’s Health Trial Study Group. J Natl Cancer Inst 82:129–134PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Paola Muti
    • 1
  1. 1.Department of Social and Preventive MedicineUniversity at Buffalo, State University of New YorkBuffaloUSA

Personalised recommendations